After injection, the undergoes enzymatic cleavage into the active component is winny steroid and decanoic acid.
The apparent volume of distribution. Binding to plasma proteins is approximately 99%. The maximum concentration serum reached the end of the first week after insertion. Serum concentration decreases exponentially with a half-life of approximately three weeks, reflecting the release rate of the drug from the depot; the equilibrium concentration is reached after about 3 months of treatment.
Slightly crosses the placental barrier in small amounts excreted in breast milk. The metabolites have no antipsychotic activity; distinguished mainly with faeces and partially urine. The half-life is approximately 35 hours.
Administered intramuscularly at a dose of 40 mg 1 time in 2 weeks, equivalent to a daily intake oral dose of 10 mg / day for 2 weeks.
Schizophrenia and other psychotic conditions, occurring with hallucinations, delusions and thought disorder, accompanied by apathy, anergy, depression and autism.
: Hypersensitivity to flupentixol or any of the excipients (including known hypersensitivity to phenothiazines).
Vascular collapse, depression of consciousness of any origin (including those caused by the intake of alcohol, barbiturates or opiates), coma. Children’s age (18 years).
C carefully: organic winny steroid brain disease, seizure disorders, severe hepatic insufficiency, hypokalemia, hypomagnesemia, cardiovascular disease history (risk of transient reduction in blood pressure), including QT prolongation, bradycardia <50 bpm, recent acute myocardial infarction, uncompensated heart failure, arrhythmias; the presence of risk factors for stroke, glaucoma (or predisposition to it), gastric ulcer and duodenal ulcer, alcoholism (can be enhanced CNS depression); pheochromocytoma, leukopenia; respiratory failure associated with acute infectious diseases, asthma or emphysema; Parkinson’s disease (enhancement of extrapyramidal effects), urinary retention, prostatic hyperplasia with clinical symptoms (urinary retention risk), Reye’s syndrome (increased risk of hepatotoxicity), epilepsy (as a result of reducing the seizure threshold may more frequent seizures); pregnancy, breastfeeding.
Not recommended for patients in a state of agitation because Flyuanksola activating effect in small doses (10-20 mg 1 time in 2 weeks) may lead to an aggravation of the symptoms.
Dosing and Administration
Flyuanksol administered by deep intramuscular injection into the upper outer quadrant of the gluteal region. It is not recommended to enter in the other muscles. If the required volume of the solution exceeds 2 ml, it is recommended to divide it into two parts and make the two injections.
Flyuanksol 20 mg / ml:
When the maintenance treatment dosage range is usually 20-40 mg (2.1 ml) every 2-4 weeks. Some patients may require higher doses or shorter intervals between injections.
In an acute exacerbation or recurrence of disease may require administration of the drug at a dose up to 400 mg at one time at intervals of 2 or even 1 week.
Flyuanksol 100 mg / ml:
dosing range is usually 50 mg (0.5 ml) every 4 weeks – 300 mg (3 ml) every 2 weeks. Some patients may require up to 400 mg dose (4 mL) in a week.
After the relief of acute symptoms produced a gradual reduction to maintenance dosage dose – typically 20-200 mg every 2-4 weeks.
When switching from treatment with oral forms Flyuanksola maintenance treatment Flyuanksolom, administered intramuscularly, should be guided by the following scheme:
The daily dose Flyuanksola tablets in mg multiplied for intramuscular injection administration at intervals of 2 weeks.
Thus for first week after the first injection should continue oral winny steroid, but at a reduced dose.
Patients who are transferred from therapy depot forms other preparations should receive a dose in the ratio: 40 mg flupenthixol decanoate equivalent to 25 mg of fluphenazine decanoate, 200 mg zuclopenthixol decanoate or 50 mg haloperidol decanoate.
Subsequent doses and intervals between injections must be set in accordance with the clinical results.
The maximum administered intramuscularly, 400 mg simultaneously with the interval between injections in one week.